ClinicalTrials.gg
RecruitingNCT07655804Updated Jul 6, 2026

Subcutaneous Calcitonin in Acute Herpes Zoster

A Phase 3 interventional study of Calcitonin and Saline in Calcitonin, Subcutaneous and Acute Herpes Zoster, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Tanta University · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.

Read the detailed description

Herpes zoster is associated with inflammation of the dorsal root ganglion and peripheral nerves, and this inflammation is considered to be an important causative factor for postherpetic neuralgia.

Interventions aimed at reducing this inflammation should therefore be effective in decreasing the likelihood of developing postherpetic neuralgia. Epidural administration of corticosteroids and local anesthetics has been shown to be effective, but is associated with the risk of arachnoiditis. Subcutaneous injection in an outpatient setting may be effective in preventing postherpetic neuralgia and is also considerably safer. Calcitonin has previously been shown to be effective in the management of acute pain following amputation. Also it was used in a previous study to prevent complex regional pain syndrome in severe hemiplegic patients after stroke. Also, a previous case report revealed that IV calcitonin provided immediate and sustained improvement in post herpetic neuralgia for over two months, without adverse effects from the calcitonin therapy.

However, no previous trials evaluated the effect of subcutaneous calcitonin as a preventive measure against the development of postherpetic neuralgia. We will conduct this study as we hypothesize that calcitonin therapy in patients with acute herpes zoster may be associated with better acute pain control and therefore may decrease the incidence of postherpetic neuralgia.

02

Conditions studied

  • Calcitonin
  • Subcutaneous
  • Acute Herpes Zoster

Browse trials for

03

In context

Herpes Zoster

300 studies on the registry are indexed under Herpes Zoster; 56 are open to participants now.

This study's planned enrollment of 168 is close to the median of 160 across 248 interventional studies indexed under Herpes Zoster.

Browse Herpes Zoster studies →

Lead sponsor

Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients aged ≥ 50 years, with acute herpes zoster infection (rash duration \< 7 days) and moderate to severe pain.

Exclusion criteria

Exclusion Criteria:

  • Coagulation abnormalities
  • Pre-existing other pain syndrome or psychological disorders.
  • Severe hepatic, cardiovascular, or renal disorders.
  • Allergy to calcitonin.
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
168 participants (estimated)

Study arms

  • Experimental
    Calcitonin group

    patients will receive subcutaneous salmon calcitonin 100 IU (ampoule = 1 ml) daily for three weeks.

    Drug: Calcitonin

  • Placebo comparator
    Control group

    patients will receive subcutaneous saline (1 ml) daily for three weeks.

    Other: Saline

Interventions

  • patients will receive subcutaneous salmon calcitonin 100 IU (ampoule = 1 ml) daily for three weeks

  • OtherSaline

    patients will receive subcutaneous saline (1 ml) daily for three weeks.

06

What researchers measure

Primary outcomes

  1. Incidence of postherpetic neuralgia at 3 months after rash onset.

    A numeric rating scale (NRS) that ranged from 0 for "no pain" to 10 for "worst ever pain will be used to assess the degree of pain. Pain score more than (3) at 3 months after onset of acute herpes zoster rash will be considered positive for the occurrence of postherpetic neuralgia.

    Time frame: 3 months after onset of acute herpes zoster rash.

Secondary outcomes

  1. Incidence of postherpetic neuralgia.

    Pain score more than 3.

    Time frame: 6 months after onset of acute herpes zoster rash.

  2. Severity of acute herpes zoster pain.

    A numeric rating scale (NRS) that ranged from 0 for "no pain" to 10 for "worst ever pain will be used to assess the degree of pain.

    Time frame: Up to 1 month after onset of acute herpes zoster rash.

  3. Number of medications used to treat pain.

    Analgesics, anti-neuropathic pain medications and opioids will be recorded.

    Time frame: up to 6 months after onset of acute herpes zoster rash.

  4. Side effects

    Vomiting

    Time frame: Up to 1 month after onset of acute herpes zoster rash.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After completion of the study.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Apr 2027, 9 months after the start.

Of 40 phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2026
First posted
Jun 18, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07655804
Lead sponsor
Tanta University
Responsible party
Amira Elkabalawy (Assistant professor of anesthesiology, surgical intensive care and pain medicine Tanta university, Tanta University) — Principal investigator
First posted
Jun 18, 2026
Start date
Jul 1, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Jul 6, 2026

Study contacts

Amira M Elkeblawy, MD
Contact
marmoramero999@gmail.com
01148529429 ext. 002

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Calcitonin

Start the discussion